Valvular & structural heart disease
Association Between Serum Albumin and Outcomes in Heart Failure and Secondary Mitral Regurgitation: The COAPT Trial
Primary result · All-cause deathResult — go to the resultAdjusted hazard ratio 1.34 95% CI 1.02–1.74Authors' conclusion
Low baseline serum albumin levels were independently associated with reduced 4-year survival in patients with HF and severe SMR enrolled in the COAPT trial, but not with HFH.
Study context
- Population
- Patients with symptomatic heart failure (HF) and moderate-to-severe or severe secondary mitral regurgitation (SMR) randomised to transcatheter edge-to-edge repair (TEER) (MitraClip) plus guideline-directed medical therapy (GDMT) vs GDMT alone559 with baseline albumin
- Participants
- 614 patients
- Comparison
- Albumin <4.0 g/dl vs ≥4.0 g/dl
- Primary endpoint
- All-cause death by baseline serum albumin
- Follow-up
- 4 years
Primary result
All-cause death
Adjusted hazard ratio
1.34
95% CI 1.02–1.74
P = 0.032
By group
Albumin <4.0 g/dlvs Albumin ≥4.0 g/dl
adjusted HR 1.34 (95% CI 1.02–1.74); P = 0.032
As reported in the abstract
Further findings
Baseline serum albumin · enrolment
- Median baseline albumin (IQR 3.7-4.2 g/dl)
- 4.0 g/dl
HF hospitalizations (HFH) and all-cause hospitalizations
- No significant differences according to baseline serum albumin level
TEER plus GDMT vs GDMT alone, by albumin level (subgroup)
- Relative effectiveness consistent in low and high albumin; interaction P for death
- 0.19
- Interaction P for HFH
- 0.35
Original publication
Association Between Serum Albumin and Outcomes in Heart Failure and Secondary Mitral Regurgitation: The COAPT Trial. Eur J Heart Fail. Published 7 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →